Methods for using human monoclonal antibodies to interleukin-5

Details Methods for using human monoclonal antibodies to interleukin-5 Methods for using human monoclonal antibodies to interleukin-5

2006-10-04

2008-09-09

Mertz, Prema (Department: 1646)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

Monoclonal antibody or fragment thereof

C424S145100

Reexamination Certificate

active

07422742

ABSTRACT:
The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to interleukin 5 (IL-5), which is preferably human IL-5. The invention also relates to human anti-IL-5 antibodies, including chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulin molecules derived from anti-IL-5 antibodies and nucleic acid molecules encoding such molecules. The present invention also relates to methods of making anti-IL-5 antibodies, pharmaceutical compositions comprising these antibodies and methods of using the antibodies and compositions thereof for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-IL-5 antibodies. The invention also relates to gene therapy methods and transgenic animals comprising nucleic acid molecules of the present invention.

REFERENCES:
patent: 5096704 (1992-03-01), Coffman et al.
patent: 5545806 (1996-08-01), Lonberg et al.
patent: 5545807 (1996-08-01), Surani et al.
patent: 5591669 (1997-01-01), Krimpenfort et al.
patent: 5612205 (1997-03-01), Kay et al.
patent: 5625126 (1997-04-01), Lonberg et al.
patent: 5633425 (1997-05-01), Lonberg et al.
patent: 5643763 (1997-07-01), Dunn et al.
patent: 5661016 (1997-08-01), Lonberg et al.
patent: 5683892 (1997-11-01), Ames, Jr. et al.
patent: 5721367 (1998-02-01), Kay et al.
patent: 5770429 (1998-06-01), Lonberg et al.
patent: 5789215 (1998-08-01), Berns et al.
patent: 5789650 (1998-08-01), Lonberg et al.
patent: 5814318 (1998-09-01), Lonberg et al.
patent: 5877293 (1999-03-01), Adair et al.
patent: 5886152 (1999-03-01), Nakatani et al.
patent: 5916771 (1999-06-01), Hori et al.
patent: 5939598 (1999-08-01), Kucherlapati et al.
patent: 5985615 (1999-11-01), Jakobovits et al.
patent: 5994619 (1999-11-01), Stice et al.
patent: 5998209 (1999-12-01), Jakobovits et al.
patent: 6054297 (2000-04-01), Carter et al.
patent: 6075181 (2000-06-01), Kucherlapati et al.
patent: 6091001 (2000-07-01), Jakobovits et al.
patent: 6114598 (2000-09-01), Kucherlapati et al.
patent: 6129913 (2000-10-01), Ames et al.
patent: 6130364 (2000-10-01), Jakobovits et al.
patent: 6632927 (2003-10-01), Adair et al.
patent: 7141653 (2006-11-01), Greenfeder et al.
patent: 2002/0142374 (2002-10-01), Gallo et al.
patent: 0267779 (1988-05-01), None
patent: 0367596 (1990-05-01), None
patent: WO 91/10741 (1991-07-01), None
patent: WO 92/01047 (1992-01-01), None
patent: WO 93/06213 (1993-04-01), None
patent: WO 93/16184 (1993-08-01), None
patent: WO 94/02602 (1994-02-01), None
patent: WO 96/33735 (1996-10-01), None
patent: WO 96/34096 (1996-10-01), None
patent: WO 98/16654 (1998-04-01), None
patent: WO 98/24893 (1998-06-01), None
patent: WO 98/50433 (1998-11-01), None
patent: WO 99/45031 (1999-09-01), None
patent: WO 99/53049 (1999-10-01), None
patent: WO 00/09560 (2000-02-01), None
patent: WO 00/37504 (2000-06-01), None
patent: WO 01/62287 (2001-08-01), None
Wilson et al. (2005) Journal of Experimental Medicine, vol. 202, No. 9, 2005, pp. 1199-1212.
Maynard, Jennifer, et al., “Antibody Engineering”,Annu. Rev. Biomed. Eng., vol. 02:339-76 (2000).
Green, Larry L., “Antibody engineering via genetic engineering of the mouse: XenoMouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies”,Journal of Immunological Methods, vol. 231:11-23, (Dec. 1999).
Dickason, Richard R., et al., “Delineation of IL-5 Domains Predicted to Engage the IL-5 Receptor Complex”,The Journal of Immunology, vol. 156:1030-1037, (Feb. 1996).
Cornelis, Sigrid, et al., “Detailed analysis of the IL-5-IL5Ralpha interaction: characterization of crucial residues on the ligand and the receptor”, The EMBO Journal, vol. 14:14,3395-3402 (Jul. 1995).
Dickason, Richard R., et al., “Enhanced detection of human IL-5 in biological fluids utilizing murine monoclonal antibodies which delineate distinct neutralizing epitopes”, Cytokine, vol. 6:6, 647-656 (Nov. 1994).
Zhang, Ji., et al., “Mapping and characterization of the epitope(s) of Sch 55700, a humanized mAb, that inhibits human IL-5”, International Immunology, vol. 11:12, 1935-1943 (Dec. 1999).
Griffiths, Andrew D., et al., “Isolationof high affinity human antibodies directly from large synthetic repertoires”, The EMBO Journal, vol. 13:14, 3245-3260 (Jul. 1994).
Zabeau, Lennart., et al., “Neutralizing monoclonal antibodies can potentiate IL-5 signaling”, Euro. J. Immunol., vol. 31:1087-1097 (Apr. 2001).
Rizzo, Charles A., et al., “The IL-5 receptor on human bronchus selectively primes for hyperresponsiveness”, J. Allergy Clin. Immunol., vol. 109:404-409 (Mar. 2002).
Panka, et al., “Variable region framework differences result in decreased or increased affinity of variant anti-digokin antibodies”, Proc. Natl. Acad. Sci. USA, vol. 85, pp. 3080-3084 (May 1988).
Rudikoff, et al., “Single amino acid substitution altering antigen-binding specificity”, Proc. Natl. Acad. Sci. USA, vol. 79, pp. 1979-1983 (Mar. 1982).
Amit, et al., “Three-dimensional structure of an antigen-antibody complex at 2.8 a resolution”, Science, vol. 233, pp. 747-753 (Aug. 1986).
International Search Report for International Application No. PCT/US03/09260.
Bird, Robert E., et al., “Single-Chain Antigen-Binding Proteins”, Science 242:423-426 (Oct. 1988).
Egan, Robert W., et al., “Effect of Sch 55700, a Humanized monoclonal Antibody to Human Interleukin-5, on Eosinophilic Responses and Bronchial Hyperreactivity”, Arzneim.-Forsch./Drug Res. 49(II), Nr. 9:779-790 (Sep. 1999).
Egan, Robert W., et al., “Inhibition of Pulmonary Eosinophilia and Hyperreactivity by Antibodies to Interleukin-5”, Int. Arch Allergy Immunol. 107(1-3):321-322 (May 1995).
Fanger, Michael W., et al., “Production and Use of Anti-FcR Bispecific Antibodies”, Immunomethods, 4:72-81 (Feb. 1994).
Galfre, G., et al., “Preparationof Monoclonal Antibodies: Strategies and Procedures”, Methods in Enzymology, 73:3-46 (1981).
Green, Larry L., et al., “Regulation of B Cell Development by Variable Gene Complexity in Mice Reconstituted with Human Immunoglobulin Yeast Artificial Chromosomes”, J. Exp. Med. 188(3):483-495 (Aug. 1998).
Green, LL., et al., “Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs”, Nature Genetics 7:13-21 (May 1994).
Greenfeder, Scott, et al., “Th2 cytokines and asthma. The role of interleukin-5 in allergic eosinophilic disease”, Respiratory Research 2(2):71-79 (Mar. 8, 2001).
Griffiths, Andrew D., et al., “Human anti-self antibodies with high specificity from phage display libraries”, The EMBO Journal 12(2):725-734 (Feb. 1993).
Holliger, Philipp, et al., “Diabodies: Small bivalent and bispecific antibody fragments”, Proc Natl. Acad. Sci. USA 90:6444-6448 (Jul. 1993).
Huston, James S., et al., “Protein engineering of antibody binding sites: Recovery of specific activity in an anti-digoxin single-chain Fv analogue produced inEscherichia coli”, Proc Natl. Acad. Sci. USA 85:5879-5883 (Aug. 1988).
Ill, Charles R., et al., “Design and construction of a hybrid immunoglobulin domain with properties of both heavy and light chain variable regions”, Protein Engineering 10(8):949-957 (Aug. 1997).
Kostelny, Sheri A., et al., “Formation of a bispecific antibody by the use of leucine zippers”, The Journal of Immunology 148(5):1547-1553 (Mar. 1992).
Kung, Ted T., et al., “Mechanisms of allergic pulmonary eosinophilia”, J. Allergy Clin. Immunol 94(6):1217-1224 (Dec. 1994).
Martin, Franck, et al., “The affinity-selection of a minibody polypeptide inhibitor of human interleukin-6”, The EMBO Jou

Affiliated with

Also associated with

Rating

Methods for using human monoclonal antibodies to interleukin-5 does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods for using human monoclonal antibodies to interleukin-5, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for using human monoclonal antibodies to interleukin-5 will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3979187